



Illinois Prescription Monitoring Program July 2026 Update



Subscribe to @ILPMP on YouTube

UPDATES

New Illinois Law Expands Prescription History Checking Requirements Prior To Prescribing



Illinois [Public Act 104-0512](#), effective June 26, 2026, expands the ILPMP prescription checking requirements. Each prescriber or prescriber's designee shall document an attempt to access and review the patient's ILPMP profile prior to prescribing any C-II opioid, C-IV benzodiazepine, and an initial C-II stimulant prescription. This expanded checking requirement reflects ILPMP's continued commitment to supporting safe prescribing practices, improving patient safety, and advancing public health initiatives across Illinois.



ILPMP Appoints New Advisory Committee Member

The ILPMP is pleased to welcome Dr. Carol DesLauiers, PharmD, DABAT, as the newest member of ILPMP Advisory Committee. Dr. DesLauiers received her Doctor of Pharmacy degree from the University of Illinois at Chicago, College of Pharmacy. She is currently serving as the Vice President of the Illinois Health and Hospital Association and leads the Illinois Poison Center.

We are excited to welcome her to the ILPMP Advisory Committee and look forward to the valuable insights and expertise she will bring to our work.

Important Update: ILPMP Reporting Requirements for Testosterone

Illinois [Public Act 104-0535](#), effective June 29, 2026, amends the Illinois Controlled Substances Act to exclude testosterone from the reporting requirements of the ILPMP. All testosterone prescription data will be purged from the ILPMP database no later than January 1, 2027.



Effective immediately, dispensers should no longer report the dispensing of testosterone to the ILPMP.


The Illinois Department of Human Services (IDHS) is updating the ILPMP database and related reporting guidance to implement this statutory change.

If testosterone is the only medication reported to the ILPMP, the pharmacy should complete a data submission waiver [here](#). Completing the waiver will stop the pharmacy from receiving non-compliance emails related to not submitting dispensations daily.

If the pharmacy manually submits dispensations to the ILPMP, the pharmacy will no longer be required to submit testosterone dispensations and should only submit other scheduled II, III, IV, and V controlled substances and drugs of interest. If there is nothing other than testosterone dispensed in a day, the pharmacy should manually submit a zero report.

Please note that while testosterone is no longer reportable to the ILPMP, dispensers should continue to exercise appropriate professional judgment and follow applicable federal and state laws, regulations,

and standards of practice to help prevent the misuse, diversion, and inappropriate prescribing or dispensing of testosterone.



ILPMP PHARMACY COMPLIANCE



Did you miss our recent webinar series? Catch up at your convenience by exploring our ILPMP Pharmacy Compliance [Playlist](#), featuring all sessions in one place.

Please contact the Pharmacy Compliance Team at DHS.DBHR.PharmacyCompliance@Illinois.gov with any questions or ideas for future materials.

EDUCATIONAL RESOURCES

The Safe Opioid Prescribing Series

Target Audience: Prescribers and Pharmacists

Cost: **FREE**

Register for (10) 30-minute online modules collectively fulfilling 5 hours CME credit.

[Register For CME Modules](#)

Navigating Pain Management, Safe Opioid Prescribing, Opioid Use Disorder

Target Audience: Pharmacists

Cost: **FREE**

Register for (10) 30-minute online modules collectively fulfilling 5 hours CE credit.

[Register for CE Modules](#)

Data Quality in Prescription Monitoring Programs

Target Audience: Pharmacists, Pharmacy Technicians, Dispensing Practitioners, and any other Data Submitters


Cost: **FREE**

Free ACPE accredited educational opportunity providing 1 hour of continuing education for pharmacists and pharmacy technicians. This program, developed in partnership with NASCSA and 12 prescription monitoring program (PMP) administrators, analyzes the importance and value of complete, accurate data reported by dispensers to PMPs and assesses the impact of intentional or non-intentional data entry errors and data omissions on patient safety. It also discusses the downstream impacts of pharmacy-reported PMP data on clinical decision-making processes and helps pharmacy staff identify and implement changes that can be made in their practice setting to improve PMP data integrity. **If you received credit for this CE prior to 10/20/25, this CE opportunity is available to you again to participate in and receive credit.**

<https://ce.talemhealth.com/a/LPMBSE>

Register For CE

ILPMP.ORG & Illinois PMPnow Monthly Data Totals



CONTACT US

✉ **DHS.DBHR.PharmacyCompliance@illinois.gov**
✉ **DHS.DBHR.PMPnow@illinois.gov**
✉ **DHS.PMP@illinois.gov**
🌐 **ILPMP.ORG**



The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data for Schedule II–V controlled substances, except for testosterone. In addition, the ILPMP requires the reporting of select drugs of interest and provides access to other relevant health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.

Illinois Prescription Monitoring Program | 401 North 4th Street | Springfield, IL 62702 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email & social marketing for free!